Quick Answer
Unicycive Therapeutics, Inc. reported Research And Development Expense of $9.12 million for the year ending 2025.
- Unicycive Therapeutics, Inc. showed a decrease of -54.4% in Research And Development Expense from 2024 to 2025.
- This data is from Unicycive Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $182.0 thousand | Q3 2020: $304.0 thousand | Q1 2021: $450.0 thousand | Q2 2021: $493.0 thousand | Q3 2021: $3.78 million | Q1 2022: $1.93 million | Q2 2022: $1.86 million | Q3 2022: $4.80 million | Q1 2023: $3.03 million | Q2 2023: $2.27 million | Q3 2023: $3.37 million | Q1 2024: $6.81 million | Q2 2024: $4.87 million | Q3 2024: $3.05 million | Q1 2025: $2.17 million | Q2 2025: $1.75 million | Q3 2025: $2.96 million.
- Over the full 6 years of available data (2020 to 2025), Unicycive Therapeutics, Inc.'s Research And Development Expense has grown by 798.6%.
- Historical annual values: Fiscal year 2025: $9.12 million | Fiscal year 2024: $20.01 million | Fiscal year 2023: $12.90 million | Fiscal year 2022: $12.44 million | Fiscal year 2021: $6.08 million | Fiscal year 2020: $1.02 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: